Related Experiment Video
Updated: Aug 21, 2026
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Pars plana vitrectomy for refractory diabetic macular edema
Ruben Grigorian1, Neelakshi Bhagat, Paolo Lanzetta
1Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark 01701-1709, USA.
Objective:
The aim of this study is to describe the results of pars plana vitrectomy (PPV) for refractory diabetic macular edema (DME).
Methods:
Review of the relevant peer-reviewed scientific literature identified using Medline.
Main Outcome Measures:
The anatomical and functional outcome of surgery.
Results:
Vitrectomy with or without internal limiting membrane (ILM) peeling can be beneficial for the treatment of DME that is resistant to laser photocoagulation or sub-Tenon's steroid injection. Visual improvement has been reported in approximately 40-90% of patients, with approximately 85-100% experiencing either improvement or stabilization of vision. Retinal edema decreases or resolves in approximately 70-100% of patients. Complications range in severity with approximately 5-20% of patients developing peripheral retinal breaks, approximately 1-2% developing retinal detachment, approximately 2% developing macular hole, and approximately 10-60% developing cataract. Severe complications such as rubeosis iridis and the fibrinoid syndrome have also been reported.
Conclusion:
Pars plana vitrectomy can be an effective treatment for diabetic macular edema refractory to laser therapy and/or sub-Tenon's capsule steroid injection.
